Product Description
Autologous, tumor-derived, heat shock protein
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cure&Sure Biotech
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Liver Cancer
Phase 2: Pancreatic Cancer|Liver Cancer|Adenocarcinoma|Gastrointestinal Cancer|Glioma|Glioblastoma
Phase 1: Non-Small-Cell Lung Cancer|Glioma|Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2500095862 | N/A |
Not yet recruiting |
Gastrointestinal Cancer|Lung Cancer |
2027-12-31 |
|
| ChiCTR2500095754 | N/A |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2027-12-31 |
|
| ChiCTR2400083881 | N/A |
Not yet recruiting |
Non-Small-Cell Lung Cancer|Hepatocellular Carcinoma |
2027-04-30 |
|
| ChiCTR2300072934 | N/A |
Recruiting |
Healthy Volunteers |
2025-03-30 |